ZANTAC
LOE ApproachingNDAORALSYRUP
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC is an oral syrup formulation of a small-molecule histamine H2-receptor antagonist approved in 1988 for acid-related gastrointestinal disorders. The drug reduces gastric acid secretion and is used to treat and prevent conditions such as peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. It represents a foundational therapy in the H2-antagonist class, now competing against proton pump inhibitors (PPIs) in a mature market.
LOE Approaching
Product is in late-stage lifecycle with declining exclusivity; commercial teams are likely focused on cost management, generic transition planning, and potential repositioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
ZANTAC offers limited growth-oriented career opportunities; roles center on managing LOE, optimizing manufacturing efficiency, and navigating generic/OTC transitions. This assignment is best suited for professionals experienced in lifecycle management, cost reduction, and mature product stewardship rather than commercial launch.
Brand Manager
Worked on ZANTAC at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.